⚠️ Educational Content Only: This page is for informational purposes and does NOT constitute medical advice. Never use prescription or research-only peptides without a licensed healthcare provider's supervision. Always consult your doctor before starting any new treatment.
GLP-1 (Glucagon-Like Peptide-1) is the hormone at the heart of most weight-loss peptide research. Here's the step-by-step of what actually happens in your body — in plain English.
After a meal, your gut releases GLP-1 hormone naturally as a signal that food has arrived.
GLP-1 travels to your brain's hypothalamus, triggering 'I'm full' signals and reducing appetite.
Gastric emptying slows — food stays in your stomach longer, extending that full feeling.
GLP-1 helps the pancreas release insulin only when needed, reducing blood sugar spikes.
With better insulin sensitivity and reduced caloric intake, your body taps into fat stores more efficiently.
The combined effect: less hunger + smaller meals + better metabolism = sustainable weight loss.
Tap any card to expand the full research breakdown. We've color-coded by FDA status so you always know where a peptide stands. 🔬
Wegovy / Ozempic
Zepbound / Mounjaro
The Triple Threat
Cagrilintide + Semaglutide
Egrifta
The Gentle Giant
The Long-Lasting Booster
The Exercise Mimetic
The Fat Fragment
Wegovy / Ozempic
Zepbound / Mounjaro
Egrifta
The Triple Threat
Cagrilintide + Semaglutide
The Gentle Giant
The Long-Lasting Booster
The Exercise Mimetic
The Fat Fragment
Average body weight reduction percentages from clinical trial data. Approved drugs are proven numbers — trial drugs are from Phase 2/3 data. Placebo included for reference.
Average % body weight reduction vs baseline
⚠️ Data from clinical trial publications. Individual results vary significantly. Trial data is preliminary and subject to change.
Understanding regulatory status before you read anything else.
| Peptide | GLP-1 | GIP | Glucagon | GH Axis | Status |
|---|---|---|---|---|---|
| Semaglutide | ✓ | – | – | – | FDA Approved |
| Tirzepatide | ✓ | ✓ | – | – | FDA Approved |
| Retatrutide | ✓ | ✓ | ✓ | – | Clinical Trials |
| CagriSema | ✓ | – | – | – | Clinical Trials |
| Tesamorelin | – | – | – | ✓ | FDA Approved |
| Ipamorelin | – | – | – | ✓ | Research Only |
From lab discovery to mainstream medicine — here's how peptide science evolved into one of the most exciting fields in health research.
Obesity affects over 1 billion people globally and is a major driver of type 2 diabetes, cardiovascular disease, and metabolic syndrome. Peptide therapies represent the first truly effective pharmacological approach to long-term weight management — a potential turning point in public health.
GLP-1 pathway discovered in the gut
First GLP-1 drug (Exenatide) approved for diabetes
Tesamorelin FDA approved for visceral fat
Semaglutide (Wegovy) approved for obesity — game changer
Tirzepatide (Zepbound) approved — dual agonist era begins
Retatrutide & CagriSema Phase 3 trials underway
Triple agonists + mitochondrial peptides on the horizon
We know this space can be confusing. Here are the most common questions we hear — answered in plain language.
A peptide is a short chain of amino acids — basically a mini protein. Your body naturally makes thousands of them to act as hormones, signaling molecules, and cellular messengers. Researchers study synthetic versions to mimic or amplify these natural processes.
Nope! GLP-1 agonists are a specific class of peptides that mimic the gut hormone GLP-1. But there are many other peptide classes — growth hormone releasers (like Ipamorelin), mitochondrial peptides (like MOTS-c), and HGH fragments (like AOD-9604) — each working through completely different mechanisms.
Currently, semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved specifically for weight management. Tesamorelin is approved only for HIV-related visceral fat. All others discussed here are either in trials or research-stage only.
This is a really important question. Many peptides sold online as 'research chemicals' are not FDA-approved for human use and carry significant risks — including unknown purity, incorrect dosing, and contamination. Always consult a licensed healthcare provider before considering any peptide therapy.
Phase 3 means the compound is in large-scale human clinical trials and on track for potential FDA review — it's close to approval. 'Research Only' means it's studied in labs or animal models and has NOT been cleared for human therapeutic use. These are very different stages!
In clinical trials, most peptide therapies showed significant weight loss even without major lifestyle changes — but results were consistently better when combined with healthier eating and activity. Think of them as powerful tools, not magic bullets.
Please read these disclaimers carefully. They're not just fine print — they're genuinely important.
All content on this page is strictly for educational and informational purposes. Nothing on this website constitutes medical advice, a diagnosis, or a treatment recommendation of any kind. This information does not replace consultation with a qualified healthcare professional.
Only semaglutide (Wegovy®), tirzepatide (Zepbound®), and tesamorelin (Egrifta®) hold FDA approval — and each only for specific approved indications. All other peptides discussed are unapproved for general weight loss use. The FDA actively warns against purchasing unapproved peptides online.
Peptides labeled 'for research use only' are not intended for human consumption. They have not been evaluated for safety, purity, or efficacy in humans. Using these compounds outside of a licensed clinical research setting carries significant and unknown health risks.
Brand names (Wegovy, Ozempic, Zepbound, Mounjaro, etc.) are mentioned solely for educational reference. House of Peptides has no commercial affiliation with any pharmaceutical company. Any commercial relationships will always be disclosed.
